Akero Therapeutics Balance Sheet Health
Financial Health criteria checks 5/6
Akero Therapeutics has a total shareholder equity of $738.3M and total debt of $35.1M, which brings its debt-to-equity ratio to 4.8%. Its total assets and total liabilities are $817.5M and $79.2M respectively.
Key information
4.8%
Debt to equity ratio
US$35.12m
Debt
| Interest coverage ratio | n/a |
| Cash | US$717.25m |
| Equity | US$738.33m |
| Total liabilities | US$79.22m |
| Total assets | US$817.55m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 0K4's short term assets ($746.9M) exceed its short term liabilities ($43.3M).
Long Term Liabilities: 0K4's short term assets ($746.9M) exceed its long term liabilities ($35.9M).
Debt to Equity History and Analysis
Debt Level: 0K4 has more cash than its total debt.
Reducing Debt: 0K4's debt to equity ratio has increased from 0% to 4.8% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 0K4 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: 0K4 has sufficient cash runway for 2.3 years if free cash flow continues to reduce at historical rates of 33.9% each year.